GNRH1 and coronary artery disorder: In male patients treated for prostate cancer, GnRH analogues have been demonstrated to increase the risk of coronary heart disease (HR, 1.16; p value < 0.001), myocardial infarction (HR, 1.11; p value = 0.03), and sudden cardiac death (HR, 1.16; p value = 0.004) [27].